Study Comparing Bupivacaine and Ropivacaine for Wisdom Tooth Removal Under General Anesthesia

What this Trial Is About

Researchers are comparing the effects of two drugs, bupivacaine and ropivacaine, in third molar wisdom tooth removal surgery under general anesthesia. This early phase 1 clinical trial aims to find out if there is any difference between these drugs regarding vital signs, bleeding control during surgery, and levels of postoperative pain in healthy volunteers aged 18 to 60 years. Participants will undergo a single third molar extraction surgery under general anesthesia. They will receive either bupivacaine 0.5% with epinephrine or ropivacaine 0.75% with epinephrine during the procedure. The study uses a split-mouth design, meaning each participant receives both drugs on different sides, allowing comparison of their effects in the same individual. During the study, participants will be monitored for vital signs and bleeding control during surgery. They will also complete the Visual Analog Scale to report postoperative pain for up to seven days following surgery. The research team will evaluate differences in pain relief, hemostasis, and vital sign changes between the two drugs. The study will last from the surgery day through the first week after the procedure.

Comparative Experimental Study Between Bupivacaine and Ropivacaine Regarding Efficacy in Third Molar Removal Surgery Under General Anesthesia